WuXi executive Dr. Chris Chen is to deliver the keynote speech at IBC’s BioProcess International China Conference in August. Chen, Senior Vice President and Chief Technology Officer, Biologics Services at WuXi, will discuss the great opportunities for large molecules in China.
In recent years we have invested heavily in China to build a world-class integrated discovery, development and manufacturing platform for biologics. The open-access biologics platform we established supports clients of any size in bringing effective and affordable large molecule drugs to market in China. It is our goal to be the gateway for novel biologics development in China.